These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 28758889)

  • 21. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bedaquiline.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
    [No Abstract]   [Full Text] [Related]  

  • 25. [Progress on the safety and efficacy of bedaquiline for the treatment of drug-resistant tuberculosis in special populations].
    Zhang YP; Niu YY; Tang PJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Jun; 46(6):619-624. PubMed ID: 37278180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.
    Furin J; Diacon AH; Andries K
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):4-5. PubMed ID: 28157457
    [No Abstract]   [Full Text] [Related]  

  • 27. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

  • 29. TMC207 becomes bedaquiline, a new anti-TB drug.
    Palomino JC; Martin A
    Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daily Dosing for Bedaquiline in Patients with Tuberculosis.
    Salinger DH; Nedelman JR; Mendel C; Spigelman M; Hermann DJ
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
    Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
    Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
    Nagabushan H; Roopadevi HS
    J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 35. A review of tuberculosis: Focus on bedaquiline.
    Chan B; Khadem TM; Brown J
    Am J Health Syst Pharm; 2013 Nov; 70(22):1984-94. PubMed ID: 24173008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil - a real-world evidence study using a retrospective design.
    Santos AP; Benace CJ; de Medeiros Leung JA; Kritski AL; de Queiroz Mello FC
    BMC Infect Dis; 2024 Oct; 24(1):1112. PubMed ID: 39375590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
    Guglielmetti L; Barkane L; Le Dû D; Marigot-Outtandy D; Robert J; Veziris N; Yazdanpanah Y; Kuksa L; Caumes E; Fréchet-Jachym M
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29419439
    [No Abstract]   [Full Text] [Related]  

  • 38. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
    Tiberi S; De Lorenzo S; Centis R; Viggiani P; D'Ambrosio L; Migliori GB
    Eur Respir J; 2014 Jan; 43(1):289-92. PubMed ID: 23988772
    [No Abstract]   [Full Text] [Related]  

  • 39. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
    Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC
    Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333
    [No Abstract]   [Full Text] [Related]  

  • 40. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
    Li Y; Sun F; Zhang W
    Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.